Advances in Research on Ferroptosis Reversing Platinum Resistance in Ovarian Cancer

Corresponding author: Zhu Weili, 1554399905@qq.com

DOI: 10.12201/bmr.202512.00070

•  

  Abstract: Ovarian cancer is the most lethal gynaecological malignancy. According to statistics, the 5-year overall survival rate of ovarian cancer is less than 30%, and most patients are already at an advanced stage when they are discovered. The current basic treatment strategy is chemotherapy after pre-cytoreductive surgery, usually platinum and taxanes. Due to the limitations of ovarian cancer treatment, even if the initial response is good, chemotherapy resistance, especially to platinum drugs, is often shown during treatment, and nearly 70% of patients will relapse within two years. The main mechanism of action of platinum drugs is to covalently bond with DNA to prevent DNA replication, and at the same time promote the formation of ROS, causing oxidative stress to damage DNA, thereby inducing apoptosis. Ferroptosis is a non-apoptotic form of cell death, so ferroptosis appears to be a tumor suppressor mechanism. The main mechanisms of ferroptosis are abnormal iron metabolism, lipid peroxidation and inhibition of the GPX4 antioxidant system, which have been confirmed to promote ferroptosis in tumor cells and reverse platinum resistance through the above three pathways. At present, many ferroptosis inducing measures have been validated, and ferroptosis inducers such as artemisinin and its derivatives are also considered to have great potential in the field of tumor treatment, but there is still a long way to go before practical application. We need to further explore the specific mechanism of drug-induced ferroptosis to maximize the benefits for patients.

  Key words: Ferroptosis; Ovarian cancer; Platinum resistance; Artemisinin; Tumor

  Submit time: 26 December 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• yanglin, yangyang. Research Progress on Autophagy-Dependent Ferroptosis in Cancer. 2024. doi: 10.12201/bmr.202410.00029

  Zhang Aiqin. Zhang Aiqins Experience in Treating Ovarian Cancer after Operation and Chemotherapy. 2024. doi: 10.12201/bmr.202411.00016

  jinmin, jinmin. Research Progress on Traditional Chinese Medicines for Reversing Bacterial Resistance and Their Mechanisms of Action. 2025. doi: 10.12201/bmr.202503.00056

  Liu Lingyan. Ferroptosis and endoplasmic reticulum stress in polycystic ovary syndrome and related potential therapeutic targets. 2025. doi: 10.12201/bmr.202507.00042

  Chen Shuling, Chen Yun, Shu Qijin. Exploring the Medication Patterns of Patent Compound Therapy for Ovarian Cancer Based on Data Mining. 2025. doi: 10.12201/bmr.202510.00008

  ZHANG Wu. Molecular mechanisms and therapeutic targets of ferroptosis in oral diseases. 2025. doi: 10.12201/bmr.202510.00005

  The current status of self-regulated fatigue in patients with recurrent ovarian cancer and its correlation with perceived burden and social supportTao Xinhui,Yu Juancai, Lin Lina. 2024. doi: 10.12201/bmr.202406.00033

  Yao Genwu, Wang Yanwei, Guo Jinyi, Li Lulu, Dang Wenbo, Song Ailin. Advances in single-cell sequencing in the breast cancer. 2024. doi: 10.12201/bmr.202407.00053

  Zhang Xinzhong. Research progress on folate receptor positive circulating tumor cells and the occurrence and development of non-small cell lung cancer. 2025. doi: 10.12201/bmr.202506.00024

  Zhao Ruiguo, Zhou Lurong, Wang Ning▲. Discussing the pathogenesis and treatment of colorectal cancer with Iron Death on the basis of “health and evil all originate from yin and yang”.. 2025. doi: 10.12201/bmr.202505.00043

• ID	Submit time	Number	Download
  1	2025-11-18	10.12201/bmr.202512.00070V1	Download

• Public  Anonymous  To author only Submit Comments